Can MS Be Stopped Early in its Tracks?

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.

Related Keywords

California ,United States ,Santa Monica ,Dallas ,Texas ,University Of Texas Southwestern Medical Center ,Amsterdam ,Noord Holland ,Netherlands ,Celgene Bristol Myers Squibb ,Viela Bio ,Barbara Giesser ,Darin Okuda ,Serono Merck ,Genentech ,Pacific Neuroscience Institute In Santa Monica ,Novartis ,Janssen Pharmaceuticals ,Osmotica Pharmaceuticals ,Serono ,Research In Multiple Sclerosis ,European Committee For Treatment ,Texas Southwestern Medical Center ,European Committee ,Multiple Sclerosis ,Medscape Medical News ,Pacific Neuroscience Institute ,Bristol Myers Squibb ,Multiple Sclerosis Ms ,Us ,Ms Lesion ,Ultiple Sclerosis Lesion ,Multiple Sclerosis Imaging ,S Imaging ,Maging In Multiple Sclerosis ,Maging In Ms ,Maging Studies In Multiple Sclerosis ,Maging Studies In Ms ,Multiple Sclerosis Progression ,Als Progression ,Multiple Sclerosis Treatment ,Als Treatment ,Reatment Of Multiple Sclerosis ,Reatment Of Ms ,Disease Modifying Therapy , ,